Report Highlights

U.S. Singleplex Immunoassay Market Overview

The U.S. singleplex immunoassay market reached USD 2.4 billion in 2024 and is projected to reach USD 4.1 billion by 2032 at a 6.9% CAGR, driven by the sustained clinical utility of single-analyte immunoassay testing across therapeutic drug monitoring, infectious disease serology, endocrinology, cardiac biomarkers, and autoimmune disease assessment that collectively constitute the highest-volume laboratory testing categories in U.S. hospital and reference laboratory settings. Singleplex immunoassays — which measure a single analyte per test reaction — remain the gold standard for high-volume routine clinical chemistry applications where the analytical validation simplicity, performance transparency, and regulatory acceptance of single-analyte platforms provide advantages over multiplex alternatives that are difficult to overcome without specific multiplex clinical utility evidence in the targeted application.

The market is served by a concentrated group of large IVD manufacturers — Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Beckman Coulter — whose integrated automated immunoassay platforms and extensive clinical test menus dominate hospital laboratory immunoassay testing through placement of their automated instruments followed by long-term reagent supply agreements. Research-grade singleplex ELISA kit markets are served by a broader supplier base including R&D Systems (Bio-Techne), BioLegend, Abcam, and Invitrogen that serve academic research and pharmaceutical preclinical applications with more flexible, less automation-dependent assay formats. The structural distinction between the clinical laboratory automated platform market and the research ELISA kit market creates two commercially distinct competitive environments within the overall singleplex immunoassay category.

Growth Drivers for U.S. Singleplex Immunoassay Market

Three growth drivers sustain the U.S. singleplex immunoassay market through 2032. Therapeutic drug monitoring expansion — driven by the growing use of biologic therapies including TNF inhibitors, monoclonal antibodies, and biologics for autoimmune, oncology, and inflammatory disease — is creating singleplex immunoassay testing volume for drug level and anti-drug antibody measurement that did not exist at commercial scale before the biologic therapy era. The proliferation of FDA-approved monoclonal antibody therapies — each requiring therapeutic drug monitoring to optimise dosing and detect immunogenicity — creates a continuous pipeline of new singleplex immunoassay test development opportunities for each newly approved biologic. Infectious disease serology — driven by expanded routine serological surveillance following COVID-19's demonstration of the clinical value of population-level antibody testing — has elevated serological immunoassay testing volume across multiple infectious disease targets including influenza, RSV, hepatitis viruses, and emerging pathogen surveillance programmes funded through CDC and BARDA infectious disease preparedness investments.

Cardiac biomarker immunoassay testing — including high-sensitivity troponin assays, NT-proBNP, and BNP — is the highest-volume growth segment within the clinical singleplex immunoassay market, driven by the American Heart Association and ACC guideline recommendations for high-sensitivity cardiac troponin as the first-line biomarker for acute myocardial infarction evaluation and the growing use of BNP and NT-proBNP for heart failure risk stratification and treatment monitoring. High-sensitivity troponin assays capable of detecting troponin concentrations below 5 ng/L — the analytical sensitivity required for the 0h/3h rapid rule-out protocols recommended in current ACC/AHA guidelines — are available only on the most advanced automated immunoassay platforms, creating both competitive differentiation for platforms achieving hs-cTn performance standards and market expansion as hospitals upgrade from conventional troponin assays to hs-cTn platforms to implement rapid rule-out pathways that reduce emergency department length of stay.

Regulatory and Reimbursement Environment

The U.S. singleplex immunoassay market's regulatory framework is governed by FDA's IVD device oversight under 21 CFR Part 820 quality system regulations and the 510(k) or PMA approval pathways that determine market entry for clinical diagnostic singleplex immunoassays. The majority of clinical singleplex immunoassays reach the U.S. market through the 510(k) substantial equivalence pathway, demonstrating analytical performance equivalent to a legally marketed predicate device without requiring new clinical evidence generation. High-risk applications — including cardiac troponin assays used in acute myocardial infarction diagnosis — undergo more rigorous FDA review that may require clinical performance data demonstrating sensitivity and specificity relative to the clinical standard of care, adding development timeline and cost relative to lower-risk immunoassay categories. The FDA's 2023 Laboratory Developed Test Proposed Rule — if finalised — would impose IVD regulatory requirements on laboratory-developed singleplex immunoassay tests currently operating without FDA oversight, potentially restructuring the research-grade immunoassay market's regulatory environment and creating both compliance costs and market consolidation pressure among laboratories operating LDT-based immunoassay testing services.

CMS reimbursement for singleplex immunoassay testing through Medicare Part B's Clinical Laboratory Fee Schedule determines the pricing economics for the large Medicare-reimbursed volume of routine clinical immunoassay testing in hospital outpatient and physician office settings. The CLFS's annual rate-setting process — which uses private payer rate data collected through the Protecting Access to Medicare Act reporting requirement — has progressively adjusted immunoassay reimbursement rates toward median private payer market rates, creating downward pricing pressure on established immunoassay codes that were previously reimbursed above market rates. New immunoassay test categories — including novel cardiac biomarkers, therapeutic drug monitoring panels, and emerging infectious disease serologies — can qualify for new CLFS codes through the AMA CPT code application process, providing initial reimbursement rates that reflect the innovation premium before the PAMA market-rate alignment process normalises rates toward median private payer levels in subsequent CLFS rate-setting cycles.

Market Opportunities in U.S. Singleplex Immunoassay Market

The neurological biomarker immunoassay segment represents the market's highest-growth emerging application, as blood-based biomarkers for Alzheimer's disease — particularly plasma phosphorylated tau (p-tau217, p-tau181) and amyloid beta 42/40 ratio measured by singleplex immunoassay platforms — achieve analytical performance sufficient to predict amyloid PET positivity and disease stage with the sensitivity and specificity that clinical utility requires. Lilly's lecanemab and donanemab FDA approvals have created clinical demand for accessible, scalable Alzheimer's disease staging biomarkers that the current standard — amyloid PET imaging at USD 4,000 per scan — cannot serve at population screening scale. Blood-based Alzheimer's biomarker immunoassays capable of ruling out amyloid burden without PET imaging would transform neurological singleplex immunoassay testing volumes by enabling primary care-level cognitive decline evaluation rather than limiting disease staging to specialist memory clinic settings with PET access.

The point-of-care singleplex immunoassay segment — lateral flow and microfluidic-based rapid immunoassays — is growing at above-market rates as the COVID-19 pandemic's normalisation of home and point-of-care testing creates sustained consumer acceptance of self-administered immunoassay testing. FDA Emergency Use Authorisation experience with rapid antigen and antibody tests accelerated the regulatory clearance pathway familiarity and consumer testing confidence that is now supporting point-of-care singleplex immunoassay expansion into influenza, RSV, strep A, and sexually transmitted infection testing categories that were previously confined to clinical laboratory settings. The point-of-care market segment's growth is being driven by retail pharmacy, urgent care, and primary care channel expansion rather than hospital laboratory growth — creating distribution channel development opportunities for POC immunoassay companies distinct from the hospital laboratory automated platform market that has historically defined the singleplex immunoassay competitive landscape.

Market at a Glance

Leading Market Participants

• Roche Diagnostics
• Abbott Laboratories (Diagnostics Division)
• Siemens Healthineers
• Beckman Coulter (Danaher)
• Bio-Techne (R&D Systems)
• BioLegend (PerkinElmer)
• Abcam
• Invitrogen (Thermo Fisher)
• EUROIMMUN (PerkinElmer)
• Ortho Clinical Diagnostics

Competitive Outlook for U.S. Singleplex Immunoassay Market

The U.S. singleplex immunoassay market will reach USD 4.1 billion by 2032, with the competitive landscape remaining concentrated among large IVD platform manufacturers in the clinical laboratory segment while becoming increasingly dynamic in the emerging neurological biomarker and point-of-care segments. The Alzheimer's blood biomarker opportunity — if blood-based p-tau217 singleplex immunoassays achieve regulatory clearance and clinical guideline integration for primary care cognitive decline evaluation before 2028 — would generate the single largest volume expansion event in the singleplex immunoassay market's recent history, converting a specialist memory clinic testing category into a primary care screening test with volume characteristics that approach the established cardiac biomarker market in testing scale. Automated platform manufacturers who develop FDA-cleared Alzheimer's blood biomarker assays for their installed automated platforms before 2028 will capture both the initial clinical adoption premium and the long-term reagent volume stream from a new high-frequency testing category that their installed base is positioned to serve without incremental platform investment by the hospital laboratory customers who have already committed to their automated immunoassay infrastructure.

The LDT regulatory rule's final implementation — if it proceeds as proposed — will represent the most significant structural disruption to the singleplex immunoassay competitive landscape since the DSHEA era for research-grade immunoassays, as it would impose FDA regulatory requirements on thousands of laboratory-developed immunoassay tests currently operating without device classification. This regulatory shift would favour large IVD manufacturers with existing FDA regulatory infrastructure over academic and specialty laboratory operators whose LDT immunoassay practices would face compliance costs exceeding their regulatory capacity, potentially consolidating significant LDT-based immunoassay testing volume toward FDA-approved commercial assays from established IVD manufacturers.